法匹拉韦治疗新型冠状病毒的应用评价与药学监护  

Application Evaluation and Pharmaceutical Care of Favipiravir in COVID-19

作　　者：洪晓冰[1] 杨琛儿 杜佳虹 余泽林 符红波 陈杰[3] HONG Xiaobing;YANG Chener;DU Jiahong;YU Zelin;FU Hongbo;CHEN Jie(Department of Pharmacy,The Second Affiliated Hospital of Shantou University of Medical College,Shantou,Guangdong 515041,China;Shantou University Medical College,Shantou,Guangdong 515041,China;Department of Pharmacy,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong 510080,China)

机构地区：[1]汕头大学第二附属医院药学部,广东汕头515041 [2]汕头大学医学院,广东汕头515041 [3]中山大学第一附属医院药学部,广东广州510080

出　　处：《今日药学》2020年第12期837-840,844,共5页Pharmacy Today

基　　金：广东省医学科学技术研究基金项目(A2019154);汕头市医疗卫生科技计划项目(汕府科〔2020〕66号-23)。

摘　　要：法匹拉韦是一种新型广谱抗病毒药物,本文从法匹拉韦的药理作用与药代动力学特征、临床应用、治疗新型冠状病毒肺炎的理论依据进行分析和总结,为临床上应用法匹拉韦治疗新型冠状病毒肺炎的安全性及有效性提供参考,提出对不同人群给予合理用药和监护建议。法匹拉韦治疗新型冠状病毒肺炎有一定作用,其适应证、最佳使用剂量、特殊人群用药及联合用药上还需要更多的研究和探索。Favipiravir is a new broad spectrum antiviral drug.This article illustrates theoretical foundation for the treatment of COVID-19 from pharmacological activity,pharmacokinetic characteristics,and clinical application.It provides reference for the safety and availability medication in clinical application of favipiravir to COVID-19 and summaries reasonable recommendation of favipiravir in therapy for different people.Favipiravir showed significantly treatment effects on COVID-19,but the indications,optimal dosage,drugs usage with special individuals and drug combination need more explorations.

关 键 词：新型冠状病毒肺炎 法匹拉韦 抗病毒药物 合理用药 药学监护 

分 类 号：R969[医药卫生—药理学]